Articles tagged with Liver Cancer
Researchers found that blocking Caspase-2 enzyme in mice increased chronic liver damage and cancer risk as they aged. The study highlights the need for caution when targeting this pathway to treat fatty liver disease.
A new rapid test for hepatitis C could identify more patients who can be cured if insurers increase reimbursement to cover the test's high cost. The test's point-of-care feature makes it ideal for early screening and treatment in clinics and emergency rooms.
A new MIT study shows that high-fat diets cause liver cells to revert to an immature state, making them more susceptible to cancer-causing mutations. This reversion is driven by genes that help the cells survive stressful conditions, but ultimately increases their likelihood of becoming cancerous.
UT Health San Antonio received $3 million in CPRIT grants to expand access to preventive salpingectomy, test novel methods to prevent liver cancer, and advance treatment for therapy-resistant metastatic breast cancer. These projects aim to improve cancer prevention, diagnosis, and treatment in South Texas.
Scientists identify targeting B-cells as a promising strategy to improve liver cancer immunotherapy. Researchers found that tumor-associated B-cells suppress T-cell activity, allowing cancer cells to escape immune attacks.
Research from Florida Atlantic University strengthens evidence that alcohol consumption increases cancer risk, particularly for breast, colorectal, and liver cancers. Higher intake and specific groups, such as African Americans and those with obesity or diabetes, are found to be more vulnerable to the risks.
A national survey of adults found that three-quarters support vaccinating newborns against hepatitis B, but Republicans are less likely to recommend the vaccine. The survey also found that most respondents believe the vaccine protects against liver disease, and there is little evidence justifying delaying vaccination.
A recent study by UCLA Health investigators found that mental health conditions significantly raise the likelihood of developing liver cancer among US veterans living with cirrhosis and hepatitis C. The study suggests that these disorders limit access to hepatitis C care, reducing the chance of a cure.
Researchers found that FOLFIRINOX improved progression-free and overall survival in patients with advanced biliary tract cancer. The treatment may offer a benefit as a second-line option after first-line chemotherapy failure, but toxicity remains a concern.
A novel liver cancer vaccine has achieved responses in a rare disease affecting children and young adults, with 75% of patients experiencing disease control. Three patients are now believed to be cancer-free after receiving the therapy, including a 13-year-old patient who achieved a nearly complete response.
The institute has opened its first specialized angiography-CT suite, integrating two forms of imaging equipment in one dedicated space. This allows interventional radiologists to perform both angiography and CT scans on the same day, reducing travel burdens for patients and improving treatment outcomes.
A new study in the Journal of Hepatology shows liver transplantation from MAiD donors yields similar survival rates as standard donation after circulatory death. This practice can significantly expand the donor pool, leading to more organs available for transplant and potentially saving thousands of lives.
Researchers identified a significant association between perfluoroheptanoic acid (PFHpA) exposure and metabolic dysfunction-associated steatotic liver disease (MASLD) in adolescents. The study used advanced models to reveal PFHpA's role in disrupting biological pathways, leading to liver damage and inflammation.
Glypican-3 is a key driver of hepatocellular carcinoma progression, facilitating metastasis and tumor microenvironment remodeling. Immunotherapy targeting GPC3 has shown preliminary safety and antitumor activity in clinical trials, with ongoing research focusing on optimized patient selection and disease monitoring.
A simple blood analysis can predict the risk of developing severe liver disease, enabling earlier detection and potentially improving treatment outcomes. The CORE model, developed by Karolinska Institutet researchers, is based on three routine blood tests and has been shown to be highly accurate in predicting liver disease risk.
Researchers have discovered myeloid cells in children's liver tumors that could be activated for treatment. This discovery provides new avenues for immunotherapy in childhood liver cancer.
The University of Cincinnati Cancer Center researchers are presenting several studies on radiation oncology, including the evaluation of efficacy and safety of proton re-irradiation in head and neck cancers, significant variation in oropharyngeal cancer treatment approaches, and severe toxicity rare following liver cancer ablative radi...
Researchers have identified CNNM4 as overexpressed in cholangiocarcinoma and found that inhibiting it, combined with GalNAc siRNA technology, can slow tumor growth and increase sensitivity to treatment. This approach could lead to personalized therapies for patients with limited treatment options.
DDX17 promotes HCC metastasis via the β-catenin/TCF4 pathway, inducing EMT and enhancing migration/invasion. The β-catenin/TCF4/DDX17 feedback loop is essential for HCC dissemination.
Researchers found that four common PFAS triggered fat buildup and cancer-related changes, with effects differing by sex. Liver cells from male and female donors responded differently to PFAS exposure.
Researchers have created a human vascularized liver cancer-on-a-chip model to evaluate vessel remodeling and cell death in response to embolic agents. This innovative platform replicates the microenvironment of liver tumors, providing unprecedented insight into how tumors respond to embolization.
Researchers at the University of Mississippi have developed a new method to deliver cancer therapies directly to triple-negative breast cancer cells. The sugar-coated nanoparticles effectively target this aggressive cancer, which affects young women and disproportionately impacts Black women. The discovery holds promise for treating no...
A new study found that a cell-based vaccine using dendritic cells can improve progression-free survival time for patients with intermediate-stage primary liver cancer. The ImmunoTACE trial showed an average of 18 months of tumor progression compared to 10 months in the control group.
The Lancet commission emphasizes the need for concrete goals to reduce hepatocellular carcinoma's growing disease burden. The authors propose a 2% annual reduction in age-standardized incidence rates and recommend evidence-based strategies to tackle viral hepatitis, alcohol consumption, environmental risk factors, and disparities in he...
Researchers have discovered a promising new approach to suppress the growth of aggressive cancers by targeting minor splicing, a specialized molecular process. By blocking minor splicing, cancer cells accumulate DNA damage and trigger cell death, while healthy cells remain largely unaffected.
Three in five liver cancer cases can be prevented by reducing viral hepatitis, alcohol consumption, and metabolic dysfunction-associated steatotic liver disease. The Lancet Commission estimates that if countries can reduce liver cancer incidence by 2-5% annually by 2050, it could prevent 9-17 million new cases and save 8-15 million lives.
A recent national study reveals complex patterns of burden and survival trends for digestive system malignancies (DSMTs) in China. Despite progress in reducing mortality from some cancers, the overall impact remains significant, with notable disparities across demographic and geographic lines.
Researchers found Galectin-1, a sugar-binding protein, plays a critical role in helping hepatocellular carcinoma cells resist thermal ablation and thrive after being treated with high heat. Blocking Gal-1 can make thermal ablation more effective and reduce the risk of recurrence.
A new study published in the Journal of Hepatology shows that durvalumab plus GemCis significantly improves overall survival for patients with advanced biliary tract cancer. The three-year follow-up analysis found that over twice as many participants treated with durvalumab plus GemCis remained alive compared to those treated with a pl...
A recent analysis of 16 years of data on Japanese adults reveals a strong association between socioeconomic status and the incidence of five common cancers. Communities with low employment rates or low incomes show higher cancer rates compared to those with higher socioeconomic status.
A unique luminescent probe using terbium has been developed to detect β-glucuronidase, an enzyme that can aid in liver cancer diagnosis. The sensor's sensitivity and accuracy are comparable to conventional methods but at a lower cost, making it suitable for resource-limited settings.
Michael Karin, renowned for his work on chronic inflammation and cancer, will lead the Center for Metabolic and Liver Diseases at Sanford Burnham Prebys. He aims to develop new treatments for metabolic and liver diseases, which affect millions of patients worldwide.
Researchers found that hepatitis B virus worsens liver inflammation, making patients more susceptible to early cancer development caused by environmental carcinogens. Limiting carcinogen exposure or reducing inflammation may mitigate this risk.
This study confirms Lycium barbarum contains multiple components that interact with various targets and pathways to treat liver cancer. The active ingredients have good binding ability, indicating a potential therapeutic effect.
Two Purdue researchers received funding to advance university innovations. Andrew Mesecar aims to develop new treatments for hepatocellular carcinoma using patented enzyme inhibitors. Meanwhile, Pablo Zavattieri is working on a patent-pending system to address saltwater intrusion in the Panama Canal.
Researchers have discovered that TAF2 plays a pivotal role in the growth of liver cancer and can help promote tumor formation. The study's findings suggest that targeting TAF2 could lead to more effective treatments for liver cancer.
High aflatoxin levels in Ghana's maize and peanuts contribute to the country's high liver cancer rates. Experts call for research to quantify the impact of fungal toxins on the disease.
Researchers at Nagoya University have created CAR-T cells that recognize and target the Eva1 protein on cancer cells, effectively eliminating tumors in lab mice. The treatment is designed to be safer by ignoring healthy cells with low amounts of Eva1.
A new study analyzed trends over time in alcohol-linked cancer mortality across the US, finding nearly double the number of alcohol-related cancer deaths between 1990 and 2021. The burden is highest among men over 55, with liver, colorectal, and esophageal cancers seeing significant increases.
A study investigated immune-related adverse events (irAEs) in Latin American patients with advanced liver cancer treated with atezolizumab and bevacizumab. Most irAEs were mild or moderate and resolved within a month, without impacting overall survival.
A study published in the Journal of Clinical and Translational Hepatology found that oleanolic acid can restore drug sensitivity to sorafenib in sorafenib-resistant hepatocellular carcinoma cells. The compound inhibited cell invasion, migration, and upregulated fabp3 expression, leading to restored sensitivity to sorafenib.
Inhibition of Aurora kinases suppresses liver cancer cell proliferation while inducing phenotypic changes resembling normal liver cells. This dual mechanism suggests a promising new approach for liver cancer therapies.
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.
A study published in The Lancet Regional Health – Europe found that patients with low household income were more likely to be diagnosed late and receive less effective treatment for liver cancer. This highlights the need for targeted screening in deprived areas to improve early diagnosis and survival rates.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center are presenting new findings on combination therapies for liver and pancreatic cancers, including a new organoid model for personalized head and neck cancer treatment. Additionally, they are discussing the potential of liquid biopsies for cancer detection and monitoring.
Hepatocellular carcinoma is the most prevalent form of liver cancer, and liver transplantation offers a curative treatment option for appropriately selected patients. Bridging therapies, such as radiofrequency ablation and transarterial chemoembolization, can improve survival outcomes post-transplant by preventing tumor progression.
A new editorial in Oncotarget discusses how artificial intelligence can improve liver imaging by recognizing when it might be wrong. The approach, called 'uncertainty quantification,' helps clinicians better detect liver cancer and other diseases by pointing out areas in medical scans that need a second look.
A survey by the Annenberg Public Policy Center found that over half of Americans believe drinking alcohol increases their chances of developing cancer. The Surgeon General's advisory on alcohol and cancer risk also contributed to increased public awareness, with nearly 3 in 10 respondents saying they would be less likely to accept a dr...
A single-center retrospective study analyzed clinical data, imaging, histopathological manifestations, genetic testing results, and treatment effects in 48 WD patients. The study found age at diagnosis, K-F ring presence, and higher immunoglobulin G levels were associated with cirrhosis risk factors.
A comprehensive study found that people with fatty liver disease have almost twice the mortality rate of the general population. The disease is caused by overweight or obesity and increases the risk of dying from various causes, including liver disease, cancer, cardiovascular disease, and infections.
A new editorial highlights a growing concern in cancer care: radiotherapy may leave behind residual disease that can lead to worse long-term outcomes. Studies have shown that patients with residual disease are more likely to experience cancer recurrence and shorter survival, emphasizing the need for regular biopsy-based tests.
A new drug candidate has been developed to target and eliminate senescent cells in the liver, reducing fat buildup and preventing liver damage. The study demonstrates a safer and more effective approach to treating metabolic dysfunction-associated steatotic liver disease (MASLD) and potentially inhibiting liver cancer development.
Research identifies six clusters of metabolic dysfunction-associated steatotic liver disease (MASLD) with varying pathophysiology and clinical outcomes. These clusters may enable personalized risk prognosis and treatment through lifestyle modification programs and targeted therapies.
Scientists at Nagoya University have developed a new mRNA technology that can produce up to 200 times more protein than traditional methods. This breakthrough enables the creation of healthy proteins to treat illnesses or toxic proteins to kill unwanted cells.
Researchers at German Cancer Research Center discovered a guardian molecule, PROX1, that regulates cell identity and prevents cancer. PROX1's constant activity suppresses cancer driver genes, leading to reduced liver tumor growth.
A recent study suggests that prolonged exposure to low-dose traffic-derived PM2.5 particles can cause fatty liver disorder in mice. The study found changes in liver function, inflammation, and scar tissue formation, highlighting the potential health risks of air pollution on the liver.
Researchers at Terasaki Institute develop lipopeptide hydrogels to deliver peptide-based cancer vaccines, demonstrating sustained release and enhanced immune cell uptake. The system shows promise in overcoming limitations of traditional peptide-based vaccines.
Researchers reveal senescence's impact on liver health, from repair and regeneration to chronic disease progression. Emerging therapies, such as senolytic treatments, aim to selectively eliminate senescent cells while preserving healthy tissue.
Researchers discover immune cells regulate blood sugar levels by stimulating glucagon production in the pancreas. This complex neuroimmune-hormonal circuit reveals a new way the body maintains stable glucose levels, especially during periods of low energy.